Eli Lilly & Co. 

(Public, NYSE:LLY)   Watch this stock   
Find more results forLLY
Jan 28, 2010
Q4 2009 Earnings Release - 12:00PM EST - Add to calendar
Dec 10, 2009
Investment Community Meeting - 12:00PM EST - Add to calendar
Nov 13, 2009
Credit Suisse Healthcare Conference
Oct 21, 2009
Q3 2009 Earnings Conference Call
Oct 21, 2009
Q3 2009 Earnings Release
Sep 21, 2009
UBS Global Life Sciences Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 16.93% -10.17%
Operating margin 19.23% -6.42%
EBITD margin - -1.79%
Return on average assets 13.98% -7.39%
Return on average equity 40.91% -20.47%
Employees 40,800 -

Address

Lilly Corporate Center
Indianapolis, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
About Company - Wikipedia

Eli Lilly & Co. discussed on blogs

Ranking 400+ Large Cap Stocks by Analyst Ratings - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 6 hours ago
Diabetes Care: Global Investing Opportunities - BioMedReports.com - Mike Havrilla - BioMedReports.Com - 21 hours ago
Five Dividend Stocks for Long-Term Dividend Growth -- Seeking Alpha - Dividend Growth Investor - SeekingAlpha.com: Home Page - Oct 27, 2009

Eli Lilly & Co. discussions

  View all discussions »

Description

Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company’s products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its principal products include Neurosciences products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products and Other pharmaceuticals. On August 20, 2008, the Company acquired SGX Pharmaceuticals, Inc. (SGX). On November 24, 2008, the Company acquired ImClone Systems Inc. (ImClone), a biopharmaceutical company focused on advancing oncology care.

Officers and directors

John C. Lechleiter Ph.D.
Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation - Reuters
Derica W. Rice
Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation - Reuters
Frank M. Deane Ph.D.
President - Manufacturing Operations
Age: 59
Bio & Compensation - Reuters
David Ricks
President, Lilly USA, LLC
Bio & Compensation - Reuters
Bryce D. Carmine
Executive Vice President - Marketing and Sales
Age: 57
Bio & Compensation - Reuters
Jan M. Lundberg Ph.D.
Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Bio & Compensation - Reuters
Robert A. Armitage
Senior Vice President, General Counsel
Portrait Age: 60
Bio & Compensation - Reuters
Sue Mahony Ph.D.
Senior Vice President - Human Resources
Bio & Compensation - Reuters
Gino Santini
Senior Vice President - Corporate Strategy and Business Development
Portrait Age: 52
Bio & Compensation - Reuters
Bart Peterson
Senior Vice President - Corporate Affairs and Communications
Bio & Compensation - Reuters